

Dr. Allen Davidoff of XORTX Therapeutics' on developing therapies for kidney diseases and uplisting to the NASDAQ

written by InvestorNews | December 9, 2021

In a recent InvestorIntel interview, Chris Thompson spoke with Dr. Allen Davidoff, CEO of [XORTX Therapeutics Inc.](#) (NASDAQ: XRTX | TSXV: XRTX | FSE: ANU) about XORTX's recent capital raise of over US\$13.4 million as part of its uplisting to the NASDAQ and its deployment of funds as it plans several clinical trials for the next year.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Allen Davidoff explained that XORTX is a biotech pharma company focusing on developing therapies for kidney diseases including a treatment for kidney issues related to COVID-19. He went on to explain how XORTX has been focusing on progressive kidney diseases, an area where there are very few therapeutic options, and a "great opportunity" to develop drugs to satisfy this market. Dr. Davidoff mentioned that to reduce the business risk, XORTX focused on a drug that had already received a FDA "approvable letter" in the past, knowing that the safety and effectiveness of the drug is well defined, and then improved on the drug with "novel innovative formulations". Finally, he said that as a biotech pharma company with two late-stage therapies entering into Phase 3 trials, there is a potential to sign co-development deals with a large pharma company that could benefit both parties.

To watch the full interview, [click here](#).

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225, a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.

To learn more about XORTX Therapeutics Inc., [click here](#)

Chris Thompson on eResearch's Update Equity Research Report on XORTX Therapeutics Inc.

written by InvestorNews | December 9, 2021

In a recent InvestorIntel interview, Tracy Weslosky spoke with Chris Thompson, President of [eResearch Corp.](#) about his 25-page [Update Equity Research Report](#) on [XORTX Therapeutics Inc.](#) (CSE: XRX | NASDAQ: XRTX | FSE: ANU).

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Chris Thompson said that XORTX is a biotech pharma company, which is taking an existing drug, Oxypurinol, and repurposing it to develop two, unique, proprietary therapies, which could help

to solve medical needs related to elevated uric acid and its effects on the kidneys without incurring the high cost of basic research. Using its optimization technology, XORTX is developing multiple drug treatments for acute kidney injury including the type of kidney injury found in COVID-19 patients. With two drugs in stage 3 clinical trials, Chris told InvestorIntel that XORTX is “significantly undervalued” when compared to its peer companies.

To watch the full interview, [click here](#)

About eResearch Corporation

eResearch Corporation is a respected source for, institutional-quality, equity research focused primarily on small- and mid-cap companies. The purpose of the focus is to identify companies that have interesting prospects, sound management, and a significant potential for share price appreciation. eResearch complements its corporate research coverage with a diversified selection of informative, insightful, and thought-provoking research publications from a wide variety of investment professionals. The professional investment research and analysis is provided directly to the company’s subscriber network of discerning investors, and is done electronically through its website, www.eresearch.com.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and XRx-101 for Coronavirus / COVID-19 infection. Its XRx-225 is in a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid, the

material that forms kidney stones. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.

To learn more about XORTX Therapeutics Inc., [click here](#)

Disclaimer: This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on [Sedar.com](#) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.